188 related articles for article (PubMed ID: 10377391)
1. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
Takebayashi Y; Pourquier P; Yoshida A; Kohlhagen G; Pommier Y
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7196-201. PubMed ID: 10377391
[TBL] [Abstract][Full Text] [Related]
2. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Takebayashi Y; Goldwasser F; Urasaki Y; Kohlhagen G; Pommier Y
Clin Cancer Res; 2001 Jan; 7(1):185-91. PubMed ID: 11205907
[TBL] [Abstract][Full Text] [Related]
3. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.
Pommier Y; Kohlhagen G; Bailly C; Waring M; Mazumder A; Kohn KW
Biochemistry; 1996 Oct; 35(41):13303-9. PubMed ID: 8873596
[TBL] [Abstract][Full Text] [Related]
4. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
5. A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions.
Marco E; García-Nieto R; Mendieta J; Manzanares I; Cuevas C; Gago F
J Med Chem; 2002 Feb; 45(4):871-80. PubMed ID: 11831898
[TBL] [Abstract][Full Text] [Related]
6. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
[TBL] [Abstract][Full Text] [Related]
7. SV40 DNA replication inhibition by the monofunctional DNA alkylator Et743.
Dziegielewska B; Kowalski D; Beerman TA
Biochemistry; 2004 Nov; 43(44):14228-37. PubMed ID: 15518573
[TBL] [Abstract][Full Text] [Related]
8. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M
Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
10. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.
Hurley LH; Zewail-Foote M
Adv Exp Med Biol; 2001; 500():289-99. PubMed ID: 11764956
[TBL] [Abstract][Full Text] [Related]
11. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.
Zewail-Foote M; Hurley LH
J Med Chem; 1999 Jul; 42(14):2493-7. PubMed ID: 10411470
[TBL] [Abstract][Full Text] [Related]
12. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
Hendriks HR; Fiebig HH; Giavazzi R; Langdon SP; Jimeno JM; Faircloth GT
Ann Oncol; 1999 Oct; 10(10):1233-40. PubMed ID: 10586342
[TBL] [Abstract][Full Text] [Related]
13. ET743: Chemical analysis of the sea squirt Ecteinascidia turbinata ecosystem.
Manning T; Rhodes E; Loftis R; Phillips D; Demaria D; Newman D; Rudloe J
Nat Prod Res; 2006 May; 20(5):461-73. PubMed ID: 16644544
[TBL] [Abstract][Full Text] [Related]
14. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
15. Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites.
Zewail-Foote M; Hurley LH
J Am Chem Soc; 2001 Jul; 123(27):6485-95. PubMed ID: 11439034
[TBL] [Abstract][Full Text] [Related]
16. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.
Guirouilh-Barbat J; Antony S; Pommier Y
Mol Cancer Ther; 2009 Jul; 8(7):2007-14. PubMed ID: 19584237
[TBL] [Abstract][Full Text] [Related]
17. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.
Minuzzo M; Marchini S; Broggini M; Faircloth G; D'Incalci M; Mantovani R
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6780-4. PubMed ID: 10841573
[TBL] [Abstract][Full Text] [Related]
18. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
Aune GJ; Takagi K; Sordet O; Guirouilh-Barbat J; Antony S; Bohr VA; Pommier Y
Clin Cancer Res; 2008 Oct; 14(20):6449-55. PubMed ID: 18927284
[TBL] [Abstract][Full Text] [Related]
19. ET-743 (PharmaMar/NCI/Ortho Biotech).
Verschraegen CF; Glover K
Curr Opin Investig Drugs; 2001 Nov; 2(11):1631-8. PubMed ID: 11763168
[TBL] [Abstract][Full Text] [Related]
20. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
